Product Description
Hydroxyprogesterone caproate injection is a man-made progestin hormone. It is used in pregnant women to help lower the risk of giving birth too early (preterm birth or giving birth less than 37 weeks of pregnancy). This medicine is given only to pregnant women who are pregnant with one baby and who have had a preterm delivery of one baby in the past. (Sourced from: https://www.mayoclinic.org/drugs-supplements/hydroxyprogesterone-injection-route/description/drg-20074807)
Mechanisms of Action: PR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Austria | Bangladesh | Chile | China | Egypt | France | Greece | India | Ireland | Pakistan | Russia | Taiwan | Thailand | Turkey | United Arab Emirates | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|